Idioma:

Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer

Islam, K M ; Anggondowati, T ; Deviany, P E ; Ryan, J E ; Fetrick, A ; Bagenda, D ; Copur, M S ; Tolentino, A ; Vaziri, I ; McKean, H A ; Dunder, S ; Gray, J E ; Huang, C ; Ganti, A K

BMC cancer, 2019-08, Vol.19 (1), p.835-835, Article 835 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer
Autor: Islam, K M ; Anggondowati, T ; Deviany, P E ; Ryan, J E ; Fetrick, A ; Bagenda, D ; Copur, M S ; Tolentino, A ; Vaziri, I ; McKean, H A ; Dunder, S ; Gray, J E ; Huang, C ; Ganti, A K
Assuntos: Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Beliefs, opinions and attitudes ; Cancer ; Cancer diagnosis ; Cancer patients ; Cancer treatment ; Care and treatment ; Chemotherapy ; Complications and side effects ; Drug-Related Side Effects and Adverse Reactions - epidemiology ; Drug-Related Side Effects and Adverse Reactions - etiology ; Female ; Humans ; Lung cancer ; Lung Neoplasms - complications ; Lung Neoplasms - diagnosis ; Lung Neoplasms - drug therapy ; Lung Neoplasms - epidemiology ; Male ; Medical records ; Medical research ; Middle Aged ; Neoplasm Staging ; Non-small cell lung cancer ; Patient Preference ; Public opinion ; Small cell lung cancer ; Socioeconomic Factors
É parte de: BMC cancer, 2019-08, Vol.19 (1), p.835-835, Article 835
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: In the U.S., lung cancer accounts for 14% of cancer diagnoses and 28% of cancer deaths annually. Since no cure exists for advanced lung cancer, the main treatment goal is to prolong survival. Chemotherapy regimens produce side effects with different profiles. Coupling this with individual patient's preferred side effects could result in patient-centered choices leading to better treatment outcomes. There are apparently no previous studies of or tools for assessing and utilizing patient chemotherapy preferences in clinical settings. The long-term goal of the study was to facilitate patients' treatment choices for advanced-stage lung cancer. A primary aim was to determine how preferences for chemotherapy side effects relate to chemotherapy choices. An observational, longitudinal, open cohort study of patients with advanced-stage non-small cell lung cancer (NSCLC) was conducted. Data sources included patient medical records and from one to three interviews per subject. Data were analyzed using Chi-square, Fisher's Exact and McNamara's test, and logistic regression. Patients identified the top three chemotherapy side effects that they would most like to avoid: shortness of breath, bleeding, and fatigue. These side effects were similar between first and last interviews, although the rank order changed after patients experienced chemotherapy. Patients ranked drug side effects that they would most like to avoid. Patient-centered clinical care and patient-centered outcomes research are feasible and may be enhanced by stakeholder commitment. The study results are limited to patients with advanced NSCLC. Most of the subjects were White, since patients were drawn from the U.S. Midwest, a predominantly White population.
Editor: England: BioMed Central Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer

Islam, K M ; Anggondowati, T ; Deviany, P E ; Ryan, J E ; Fetrick, A ; Bagenda, D ; Copur, M S ; Tolentino, A ; Vaziri, I ; McKean, H A ; Dunder, S ; Gray, J E ; Huang, C ; Ganti, A K

England: BioMed Central Ltd

Buscando em bases de dados remotas. Favor aguardar.